The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company Vertex Pharmaceuticals on Thursday. The drug, which is called suzetrigine ...

The Summerlin master-planned community offers more than 75 unique floor plans in 15 neighborhoods throughout eight distinct ...

Vertex Pharmaceuticals rose Thursday night after ... Investors.com - Stocks Fade Late After Trump Tariff Threat; Duolingo, Square, Doximity In Focus The first-in-class drug, also known as ...

At the recent 210mm Five-Year Ecological Innovation Conference, Dr. Zhang Yingbin, Head of Strategy, Product, and Marketing at Trinasolar, took the stage to highlight the transformative impact of the ...

Protesters took to the streets of lower Manhattan to denounce and protest U.S. Immigration and Customs Enforcement (ICE) on ...

When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant.

The firm could possibly eye about $800 million for the second continuation fund. Others that have adopted this strategy include Vertex Holdings and technology investment firm Basil Partners, which was ...

and the "corners" curve is closer to the square's corners. Example 12: You can give a different size for each segment ("edges" method in yellow) or corner ("corners" method in red). The first vertex ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...